MRK

Healthcare / Pharmaceuticals & Drug Manufacturers - General
Global pharmaceutical and animal health company generating revenue through discovery, development, manufacturing, and marketing of prescription drugs, vaccines, and veterinary health solutions with high R&D intensity and patent-protected product portfolios.
Recommended: koller_dcf
$123.54
Current market price
Source: FMP +EDGAR

Market implications

What the market is baking into $123.54. Does not change with your assumptions.

Implied terminal growth (cv_g)
n/a (out of range)
WACC (CAPM)
4.73%
β: 0.20 · Rf: 4.0% · ERP: 5.5%
Ke: 5.13% · Kd(AT): 2.33%
E/V: 85.9% · D/V: 14.1%
CV ROIC (from historical)
37.04%
CV NOPLAT = $29,210M
Tax rate / Op cash / Shares
Forecast tax: 13.3%
Op cash %: 3.0%
Shares: 2,502M
5-year consensus forecast
YearRevenue ($M)EBITDA ($M)
2025 64,850 33,219
2026 66,750 34,193
2027 70,228 35,974
2028 74,832 38,333
2029 74,350 38,086
Validation: set your view's WACC = 4.73%, cv_g = ?%, tax = 13.3%. Your model should produce exactly $123.54.

Your view

Yellow cells are editable.

Your model output

Model share price: $117.34
vs market: -5.0%
Enterprise value: $331,914M
Operating value: $319,687M
Continuing value: $223,412M
Debt: $38,270M
Excess cash: $11,764M
Residuals: B/S 0.0M · TFI 0.0M · TII 0.0M · CFI 0.0M

Forecast ratios (yellow cells)

Held constant across forecast years (H–M). Defaults are the most recent historical ratio. Override to express a different view (margin compression, working-capital efficiency, etc.).

Income statement

D&A % of revenue 7.01%
Non-op losses % of rev 0.00%

Working capital

AR % of revenue 16.02%
Unbilled rev % of rev 0.00%
Inventory % of rev 9.52%
Other CA % of rev 13.57%
AP % of rev 30.81%
Other ST liab % of rev 8.91%

Long-term assets & liab

LT investments % of rev 0.72%
Net fixed assets % of rev 35.25%
Other LT assets % of rev 26.81%
Other LT liab % of rev 10.87%

Consensus forecast (your editable copy)

Defaults are FMP analyst consensus. Edit any cell; Recalculate uses these values.

YearRevenue ($M)EBITDA ($M) EBITDA marginYoY rev growth
2025 51.2% —
2026 51.2% +2.9%
2027 51.2% +5.2%
2028 51.2% +6.6%
2029 51.2% -0.6%
CV NOPLAT: $28,957M · CV ROIC: 36.72%

Sensitivity: model price by WACC × cv_g

5×5 grid centered on your assumptions. Green cells > market, red < market. Computes 25 model runs (~10s).

Click “Run sensitivity” above.

Monte Carlo simulation

Sample WACC, cv_g, revenue multiplier, and EBITDA margin shift; see distribution of fair value.

Distribution widths (σ):
Each sample: draws values from normal distributions centered on your current assumptions, runs the full DCF, records the model price. 100 samples ≈ 60s.

Configure σ above and click “Run Monte Carlo”.

Peers (LLM-proposed comparables)

3–5 publicly-traded comps with rationale + suggested multiples. ~$0.002/call, cached 30d.

▸ expand

Red flags (accounting / governance / operational / liquidity)

Severity-tiered concerns with explicit evidence. ~$0.004/call, cached 30d.

▸ expand

Recent news (web search)

Material items from the last 60 days with source links. ~$0.02–0.05/call, cached 6h.

▸ expand

Snapshots

No saved snapshots yet.